Complete regression of well-established tumors using a novel water- soluble poly(L-glutamic acid)-paclitaxel conjugate

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2404-2409

  Li, Chun ^a,b   Yu, Dong Fang ^a   Newman, Robert A ^a   Cabral, Fernando ^a   Stephens, L Clifton ^a   Hunter, Nancy ^b   Milas, Luka ^b   Wallace, Sidney ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; POLYGLUTAMIC ACID; TUBULIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MIXTURE; DRUG POTENCY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CHO CELLS; CRICETINAE; MICE; MICROTUBULES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; POLYGLUTAMIC ACID; RATS; REMISSION INDUCTION; SOLUBILITY; TAXOIDS; WATER;

EID: 0032101105     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
2. Holmes, F. A., Kudelka, A. P., Kavanagh, J. J., Huber, M. H., Ajani, J. A., and Valero, V. Current status of clinical trials with Taxol and docetaxel. In: G. I. Georg, T. T. Chen, I. Ojima, and D. M. Vyas (eds.). Taxane Anticancer Agents: Basic Science and Current Status, pp. 31-57. Washington, DC: American Chemical Society, 1995.
3. Deutsch, H. M., Glinski, J. A., Haugwitz, R. D., Narayanan, V. L., Suffness, M., and Zalkow, L. H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of paclitaxel with potent antitumor activity. J. Med. Chem., 32: 788-792, 1989.
4. Mathew, A. K., Mejillano, M. R., Nath, J. P., Himes, R. H., and Stella, V. J. Synthesis and evaluation of some water-soluble prodrugs and derivatives of paclitaxel with antitumor activity. J. Med. Chem., 35: 145-151, 1992.
5. Zhao, Z., and Kingston, D. G. I. Modified Taxols. 6. Preparation of water-soluble prodrugs of Taxol. J. Nat. Prod. (Lloydia), 54: 1607-1611, 1991.
6. Vyas, D. M., Ueda, Y., Wong, H., Matiskella, J. D., Hauck, S., Mikkilineni, A. B., Farina, V., Rose, W. C., and Casazza, A. M. Phosphatase-activated prodrugs of paclitaxel. In: G. I. Georg, T. T. Chen, I. Ojima, and D. M. Vyas (eds.), Taxane Anticancer Agents: Basic Science and Current Status, pp. 124-137. Washington, DC: American Chemical Society, 1995.
7. Rose, W. C., Clark, J. L., Lee, F. Y. F., and Casazza, A. M. Preclinical antitumor activity of water-soluble paclitaxel derivatives. Cancer Chemother. Pharmacol., 39: 486-492, 1997.
8. Nicolaou, K. C., Riemer, C., Kerr, M. A., Rideout, D., and Wrasidlo, W. Design, synthesis, and biological activity of protaxols. Nature (Lond.), 164: 464-466, 1993.
9. Maeda, H., Seymour, L. W., and Miyamoto, Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem., 3: 351-362, 1992.
10. Duncan, R., Hume, I. C., Kopeckova, P., Ulbrich, K., Strohalm, J., and Kopecek, J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of Adriamycin conjugates against mouse leukemia L1210 in vivo. J. Controlled Rel., 10: 51-63, 1989.
11. Berstein, A., Hurwitz, E., Maron, R., Arnon, R., Sela, M., and Wilchek, M. Higher antitumor efficacy of daunomycin when linked to dextran: in vitro and in vivo studies. J. Natl. Cancer Inst., 60: 379-384, 1978.
12. Trouet, A., Masquelier, M., Barurain, R., and Campeneere, D. D-D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 79: 626-629, 1982.
13. Li, C., Yu, D-F., Inoue, T., Yang, D. J., Milas, L., Hunter, N. R., Kim, E. E., and Wallace, S. Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs, 7: 642-648, 1996.
14. Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., and Martinez, A. Drug delivery systems: water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem., 39: 424-431, 1996.
15. Hoes, C. J. T., Potman, W., van Heeswijk, W. A. R., Mud, J., de Grooth, B. G., Greve, J., and Feijen, J. Optimization of macromolecular prodrugs of the antitumor antibiotic Adriamycin. J. Controlled Rel., 2: 205-213, 1985.
16. Hirano, T., Klesse, W., and Ringsdorf, H. Polymeric derivatives of activated cyclophosphamide as drug delivery systems in antitumor therapy. Makromol. Chem., 180: 1125-1130, 1979.
17. Kato, Y., Saito, M., Fukushima, H., Takeda, Y., and Hara, T. Antitumor activity of 1β-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Cancer Res., 44: 25-30, 1984.
18. Boyle, F., Monk, R., Davey, R., Wheeler, H., and Shenfield, G. Prevention of experimental paelitaxel neuropathy with glutamate. Proc. Am. Assoc. Cancer Res., 37: 290, 1996.
19. Longnecker, S. M., Donehower, R. C., Cates, A. E., Chen, T-L., Brundrett, R. B., Grochow, L. B., Ettinger, D. S., and Colvin, M. High-performance liquid Chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat. Rep., 71: 53-59, 1987.
20. Milas, L., Hunter, N. R., Kurdoglu, B., Mason, K. A., Meyn, R. E., Stephens, L. C., and Peters, L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother. Pharmacol., 35: 297-303, 1995.
21. Cabral, F., Wible, L., Brenner, S., and Brinkley, B. R. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J. Cell Biol., 97: 30-39, 1983.
22. Cabral, F., and Barlow, S. B. Resistance to antimitotic agents as genetic probes of microtubule structure and function. Pharmacol. Ther., 52: 159-171, 1991.